Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease

Expert Review of Clinical Pharmacology

Volumn 8, Issue 1, 2014, Pages 35-41

  Matera, Maria Gabriella ^a   Rogliani, Paola ^b   Rinaldi, Barbara ^a   Cazzola, Mario ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

COPD; Ellipta; fixed dose combination; umeclidinium bromide; vilanterol

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARBACHOL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDACATEROL; ISOPRENALINE; LONG ACTING BETA AGONIST; MOXIFLOXACIN; OLODATEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; UNCLASSIFIED DRUG; VILANTEROL; BENZYL ALCOHOL DERIVATIVE; BROMIDE; BRONCHODILATING AGENT; CHLOROBENZENE; DRUG COMBINATION; QUINUCLIDINE DERIVATIVE;

ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL LABORATORY; CLINICAL TRIAL (TOPIC); COMPETITIVE INHIBITION; CONSTIPATION; CORTICOSTEROID THERAPY; DIARRHEA; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; DRY POWDER INHALER; DYSPNEA; EXERCISE; HUMAN; LEG PAIN; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MUSCLE SPASM; NECK PAIN; OUTCOME ASSESSMENT; PARAMETERS; PHARYNGITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; QT PROLONGATION; QUALITY OF LIFE; SINUSITIS; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BENZYL ALCOHOLS; BROMIDES; BRONCHODILATOR AGENTS; CHLOROBENZENES; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84916928423     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2015.977256     Document Type: Article

References (58)

1. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64: 450-504
2. Cazzola M, Brusasco V, Centanni S, et al. Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists. Pulm Pharmacol Ther 2013;26:218-28
3. Cazzola M, Molimard M. The scientific rationale for combining long-acting b2- agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010;23: 257-67
4. Meurs H, Oenema TA, Kistemaker LE, Gosens R. A new perspective on muscarinic receptor antagonism in obstructive airways diseases. Curr Opin Pharmacol 2013;13: 316-23
5. Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011;32:495-506
6. Cazzola M, Rogliani P, Segreti A, Matera MG. An update on bronchodilators in Phase I and II clinical trials. Expert Opin Investig Drugs 2012;21:1489-501
7. Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther 2013;26:307-17
8. Matera MG, Rogliani P, Cazzola M. Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2014;15:961-77
9. Cazzola M, Calzetta L, Matera MG. b2-adrenoceptor agonists: current and future direction. Br J Pharmacol 2011;163:4-17
10. Cazzola M, Page CP, Rogliani P, Matera MG. b2-agonist therapy in lung disease. Am J Respir Crit Care Med 2013;187:690-6
11. Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther 2013;345:260-70
12. Church A, Beerahee M, Brooks J, et al. Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study. BMC Pulm Med 2014;14:2
13. Trivedi R, Richard N, Mehta R, Church A. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J 2014;43:72-81
14. Tal-Singer R, Cahn A, Mehta R, et al. Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies. Eur J Pharmacol 2013;701:40-8
15. Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting b2- adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther 2013;344: 218-30
16. Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther 2013;26:256-64
17. Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting b2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest 2012;142: 119-27
18. Feldman G, Walker RR, Brooks J, et al. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. Pulm Pharmacol Ther 2012;25:465-71
19. Mehta R, Hardes K, Cahn A, et al. Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults [abstract]. Eur Respir J 2011;38(Suppl 5):723s
20. Cahn A, Lovick R, Newlands A, et al. Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects [abstract]. Eur Respir J 2011; 38(Suppl 5):723s
21. Goyal N, Beerahee M, Kalberg C, et al. Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet 2014;53:637-48
22. Mehta R, Hardes K, Kelleher D, et al. Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study. Clin Ther 2014;36:1016-27
23. Kelleher D, Hardes K, Brealey N, et al. Effect of severe renal impairment (SRI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) [abstract]. Eur Respir J 2013;42(Suppl 57):P4148
24. Mehta R, Kelleher D, Preece A, et al. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study. Int J Chron Obstruct Pulmon Dis 2013;8:159-67
25. Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013;107:1538-46
26. Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/ 25 mcg in COPD: a randomized, controlled study. Chest 2014. [Epub ahead of print]
27. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2014;2:472-86
28. Decramer M, Anzueto A, Richard N, et al. Effect of the once-daily long-acting bronchodilator combination umeclidinium/ vilanterol (UMEC/VI) and bronchodilator monotherapy on dyspnoea as measured by the transitional dyspnoea index (TDI) in COPD. Eur Respir J 2014;44:P921
29. Han MK, Kalberg C, Brooks J, Church A. Bronchodilator response to the long-acting bronchodilator combination of umeclidinium/vilanterol across subgroups of patients with COPD [abstract]. Am J Respir Crit Care Med 2014;189:A3762
30. Singh D, Worsley S, Zhu CQ, et al. Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Eur Respir J 2014;44:P290
31. GlaxoSmithKline. Pulmonary Allergy Drugs Advisory Committee Meeting: FDA briefing document. NDA 203-975: umeclidinium and vilanterol inhalation powder for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). 2013. Available from: http:// www.fda.gov/downloads/advisory committees/committeesmeetingmaterials/ drugs/pulmonary-allergydrugsadvisory committee/ucm367411.pdf [Last accessed 2 September 2014]
32. Maltais F, Singh S, Donald A, et al. Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: two randomised clinical trials [abstract]. Eur Respir J 2013; 42(Suppl 57):P761
33. Huisman E, Cockle S, Punekar Y. Comparative assessment of umeclidinium/ vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients [abstract]. Eur Respir J 2013;42:P894
34. Scott LJ, Hair P. Umeclidinium/Vilanterol: first global approval. Drugs 2014;74:389-95
35. Kelleher D, Tombs L, Preece A, et al. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects. Pulm Pharmacol Ther 2014;29:49-5
36. Naccarelli G, Finkle J, Chopra B, et al. Cardiovascular safety of umeclidinium/ vilanterol in COPD: results from eight randomized clinical trials [abstract]. Am J Respir Crit Care Med 2014;189:A3766
37. Donohue JF, Niewoehner D, Brooks J, et al. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res 2014;15:78
38. Bäckman P, Adelmann H, Petersson G, Jones CB. Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product. Clin Pharmacol Ther 2014;95:509-20
39. Hamilton M, Prime D, Bogalo Huescar M, et al. In-vitro delivery performance of umeclidinium and umeclidinium/vilanterol from a dry powder inhaler using the Electronic Lung breathing simulator to replicate inhalation profiles from patients with varying COPD severity [abstract]. Am J Respir Crit Care Med 2013;187:A4281
40. Svedsater H, Dale P, Garrill K, et al. Qualitative assessment of attributes and ease of use of the ELLIPTATM dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med 2013;13:72
41. Sharma R, Komase Y, Akimoto A, Kobayashi A. Operability of the ELLIPTATM dry powder inhaler: a comparative evaluation of handling technique in inhalation therapy-naïve subjects [abstract]. Am J Respir Crit Care Med 2014;189:A5693
42. US Food and Drug Administration. FNA News Release. FDA approves Anoro Ellipta to treat chronic obstructive pulmonary disease. Available from: http:// www.fda.gov/newsevents/newsroom/ pressannouncements/ucm379057.htm [Last accessed 31 August 2014]
43. CenterWatch. Anoro Ellipta (umeclidinium and vilanterol inhalation powder). Available from: https://www.centerwatch.com/druginformation/ fda-approved-drugs/drug/1300/ anoro-ellipta-umeclidinium-and-vilanterolinhalation- powder [Last accessed 5 October 2014]
44. GlaxoSmithKline, Inc. Anoro Ellipta approved for COPD in Canada. Available from: http:/www.firstwordpharma.com/node/1177487?tsid=28®ion-id=3#axzz2qDDGAfxx [Last accessed 31 August 2014]
45. Reuters Edition UK. Glaxosmithkline Plc and Theravance Inc announce Anoro (Umeclidinium/Vilanterol) gains marketing authorisation in Europe for the treatment of COPD. Available from: http://uk.reuters. com/business/quotes/GSK.L/key- developments/article/2985715 [Last accessed 31 August 2014]
46. Theravance and GSK Receive Approval for Anoro Ellipta in Japan. Available from: http://www.outsourcedpharma.com/doc/ theravance-and-gsk-receive-approval-foranoro- ellipta-in-japan-0001 [Last accessed 31 August 2014]
47. Cazzola M, Matera MG. Bronchodilators: current and future. Clin Chest Med 2014;35:191-201
48. Cazzola M, Page C. Long-acting bronchodilators in COPD: where are we now and where are we going? Breathe 2014;10:110-20
49. Segreti A, Stirpe E, Rogliani P, Cazzola M. Defining phenotypes in COPD: an aid to personalized healthcare. Mol Diagn Ther 2014;18:381-8
50. Cazzola M, Segreti A, Bettoncelli G, et al. Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. Prim Care Respir J 2011;20:291-8
51. Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med 2012;106: 989-97
52. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2014. Available from: www. goldcopd.org [Last accessed 4 September 2014]
53. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155:179-91
54. Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic obstructive pulmonary disease. Expert Opin Pharmacother 2013;14: 2489-99
55. Miravitlles M, Calle M, Soler-Cataluna JJ. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol 2012;48:86-98
56. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008;134:255-62
57. Wedzicha JA, Decramer M, Seemungal TA. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J 2012;40:1545-54
58. Cazzola M, Segreti A, Matera MG. New developments in the combination treatment of COPD: focus on umeclidinium/ vilanterol. Drug Des Devel Ther 2013;7: 1201-8